BR112017004141B8 - Agente de imagemamento e seu uso - Google Patents
Agente de imagemamento e seu usoInfo
- Publication number
- BR112017004141B8 BR112017004141B8 BR112017004141A BR112017004141A BR112017004141B8 BR 112017004141 B8 BR112017004141 B8 BR 112017004141B8 BR 112017004141 A BR112017004141 A BR 112017004141A BR 112017004141 A BR112017004141 A BR 112017004141A BR 112017004141 B8 BR112017004141 B8 BR 112017004141B8
- Authority
- BR
- Brazil
- Prior art keywords
- imaging agent
- imaging
- probes
- compound
- formula
- Prior art date
Links
- 239000012216 imaging agent Substances 0.000 title abstract 2
- 102000016252 Huntingtin Human genes 0.000 abstract 1
- 108050004784 Huntingtin Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
- A61B5/0035—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for acquisition of images from more than one imaging mode, e.g. combining MRI and optical tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- High Energy & Nuclear Physics (AREA)
- Theoretical Computer Science (AREA)
- Pulmonology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043603P | 2014-08-29 | 2014-08-29 | |
| US62/043,603 | 2014-08-29 | ||
| PCT/US2015/047407 WO2016033445A1 (en) | 2014-08-29 | 2015-08-28 | Probes for imaging huntingtin protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112017004141A2 BR112017004141A2 (pt) | 2017-12-12 |
| BR112017004141B1 BR112017004141B1 (pt) | 2022-04-19 |
| BR112017004141B8 true BR112017004141B8 (pt) | 2022-08-02 |
Family
ID=55400648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017004141A BR112017004141B8 (pt) | 2014-08-29 | 2015-08-28 | Agente de imagemamento e seu uso |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10479802B2 (https=) |
| EP (2) | EP3186233B8 (https=) |
| JP (2) | JP6817207B2 (https=) |
| KR (2) | KR102456946B1 (https=) |
| CN (2) | CN116655618B (https=) |
| AU (1) | AU2015308774B2 (https=) |
| BR (1) | BR112017004141B8 (https=) |
| CA (1) | CA2959501C (https=) |
| DK (1) | DK3186233T3 (https=) |
| EA (1) | EA035646B1 (https=) |
| ES (1) | ES2898965T3 (https=) |
| HR (1) | HRP20211778T1 (https=) |
| HU (1) | HUE056957T2 (https=) |
| IL (1) | IL250803B (https=) |
| MX (2) | MX380810B (https=) |
| PL (1) | PL3186233T3 (https=) |
| PT (1) | PT3186233T (https=) |
| SG (1) | SG11201701600QA (https=) |
| SI (1) | SI3186233T1 (https=) |
| WO (1) | WO2016033445A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3186241B1 (en) | 2014-08-29 | 2020-10-07 | CHDI Foundation, Inc. | Probes for imaging huntington protein |
| DK3197277T3 (da) | 2014-08-29 | 2022-01-31 | Chdi Foundation Inc | Prober til billeddannelse af huntingtin-protein |
| AU2015308709B2 (en) | 2014-08-29 | 2020-01-02 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| HUE056957T2 (hu) * | 2014-08-29 | 2022-04-28 | Chdi Foundation Inc | Próbák huntingtin fehérjét megjelenítõ képalkotásra |
| PT3340796T (pt) | 2015-08-28 | 2021-07-28 | Chdi Foundation Inc | Sondas para imagens da proteína huntingtina |
| NZ746901A (en) | 2016-03-11 | 2023-06-30 | Ac Immune Sa | Bicyclic compounds for diagnosis and therapy |
| CN107056723A (zh) * | 2017-04-21 | 2017-08-18 | 云南大学 | 一种具有抑制血管内皮生长因子受体信号传导的化合物 |
| CA3075892C (en) | 2017-09-14 | 2024-01-23 | Daiichi Sankyo Company, Limited | Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases |
| AU2019254499A1 (en) | 2018-04-20 | 2020-12-03 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| IL279219B2 (en) | 2018-06-08 | 2024-08-01 | Ac Immune Sa | Novel compounds for diagnosis |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| JP7619952B2 (ja) | 2019-02-25 | 2025-01-22 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用 |
| CN111635400A (zh) | 2019-03-02 | 2020-09-08 | 察略盛医药科技(上海)有限公司 | 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 |
| JP7720847B2 (ja) * | 2019-12-18 | 2025-08-08 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ハンチンチンタンパク質をイメージングするための化合物及びプローブ |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| EP4146653A1 (en) | 2020-05-07 | 2023-03-15 | AC Immune SA | Novel compounds for diagnosis |
| WO2022031946A1 (en) * | 2020-08-06 | 2022-02-10 | Chdi Foundation, Inc. | Heterobiaryl compounds and imaging agents for imaging huntingtin protein |
| CN117412960A (zh) * | 2021-04-08 | 2024-01-16 | Chdi基金会股份有限公司 | 用于对亨廷顿蛋白成像的异吲哚啉酮化合物和显像剂 |
| AU2022264490A1 (en) * | 2021-04-27 | 2023-11-09 | Chdi Foundation, Inc. | Deuterated compounds and imaging agents for imaging huntingtin protein |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| EP4430044A1 (en) | 2021-11-10 | 2024-09-18 | AC Immune SA | Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis |
| WO2023083998A1 (en) | 2021-11-10 | 2023-05-19 | Ac Immune Sa | Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis |
| JP2024544539A (ja) | 2021-11-10 | 2024-12-03 | エーシー・イミューン・エス・アー | 診断のための４ｈ－イミダゾ［１，５－ｂ］ピラゾール誘導体 |
| TW202425965A (zh) | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| EP4634191A1 (en) | 2022-12-16 | 2025-10-22 | AC Immune SA | Novel compounds for diagnosis |
| EP4634190A1 (en) | 2022-12-16 | 2025-10-22 | AC Immune SA | Novel compounds for diagnosis |
| WO2024239000A2 (en) * | 2023-05-18 | 2024-11-21 | Enveda Therapeutics, Inc. | G-protein coupled receptor antagonist |
| WO2025037013A1 (en) | 2023-08-16 | 2025-02-20 | Ac Immune Sa | Diagnostic compounds that bind to alpha-synuclein |
| WO2025106920A1 (en) * | 2023-11-15 | 2025-05-22 | Yale University | Parp pet imaging agents and methods of using the same |
| CN119264072B (zh) * | 2024-12-06 | 2025-05-02 | 国科大杭州高等研究院 | 对细胞成像的荧光探针及其合成方法和应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985755A (en) | 1972-06-02 | 1976-10-12 | E. R. Squibb & Sons, Inc. | Pyridine containing isothiocyanobenzoxazoles |
| US4198416A (en) | 1976-09-30 | 1980-04-15 | Meiji Seika Kaisha, Ltd. | 5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters |
| DE2909754A1 (de) * | 1979-03-13 | 1980-09-18 | Thomae Gmbh Dr K | Neue benzofuran- und benzothiophenderivate, deren herstellung und deren verwendung als arzneimittel |
| FR2524468B1 (fr) | 1982-04-06 | 1985-10-18 | Sandoz Sa | Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques |
| JP2869561B2 (ja) * | 1989-05-22 | 1999-03-10 | 大塚製薬株式会社 | 血小板粘着抑制剤 |
| US5041453A (en) | 1990-05-30 | 1991-08-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 |
| JP2600644B2 (ja) | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
| GB9203798D0 (en) | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| WO1994022846A1 (en) * | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
| GB9317949D0 (en) * | 1993-08-28 | 1993-10-13 | Stevens Malcolm F G | Benzothiazole compounds |
| UA44710C2 (uk) * | 1995-02-28 | 2002-03-15 | Елі Ліллі Енд Компані | Похідні бензотіофену, спосіб їх одержання (варіанти), проміжні сполуки, фармацевтична композиція |
| JPH08325265A (ja) * | 1995-05-29 | 1996-12-10 | Fujisawa Pharmaceut Co Ltd | チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物 |
| DE69728581D1 (de) | 1996-01-22 | 2004-05-13 | Fujisawa Pharmaceutical Co | Thiazolylbenzofuranderivate und ihre Verwendung als SRS-A- und Leukotrien-Antagonisten |
| JPH11171886A (ja) | 1997-12-08 | 1999-06-29 | Mitsui Chem Inc | アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体 |
| US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| WO2003048140A1 (en) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| DE60213856T2 (de) | 2001-12-20 | 2007-09-13 | Wyeth | Indolylalkylamin-derivate als 5-hydroxytryptamin-6 liganden |
| CA2438032C (en) | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| WO2005040337A2 (en) | 2003-05-20 | 2005-05-06 | The Regents Of The University Of California | METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES |
| AU2003304416A1 (en) | 2003-08-13 | 2005-03-07 | Bf Research Institute, Inc. | Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| KR20080094699A (ko) | 2006-02-15 | 2008-10-23 | 사노피-아벤티스 | 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도 |
| CN101528226B (zh) | 2006-08-24 | 2012-01-11 | 澳大利亚核科学技术组织 | 靶向外周苯二氮卓受体的氟化配体 |
| JP5190893B2 (ja) * | 2006-12-25 | 2013-04-24 | 国立大学法人東北大学 | ベンゾキサゾール誘導体 |
| WO2008134618A2 (en) * | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
| KR101469275B1 (ko) | 2007-06-01 | 2014-12-08 | 재단법인서울대학교산학협력재단 | 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물 |
| US20100267712A1 (en) | 2007-09-27 | 2010-10-21 | The United States of America, as represented by the Secretary, Department of Health and | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US20090123373A1 (en) | 2007-11-05 | 2009-05-14 | Yanming Wang | Amyloid-imaging agents |
| US8153813B2 (en) | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| WO2009146388A1 (en) | 2008-05-28 | 2009-12-03 | The Trustees Of Columbia University In The City Of New York | Voxel-based methods for assessing subjects using positron emission tomography |
| CA2725940A1 (en) * | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted azabenzoxazoles |
| AU2009260526A1 (en) * | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted indoles |
| JP2012507534A (ja) | 2008-10-31 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 新規置換アザベンゾオキサゾール類 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| US8815918B2 (en) | 2009-04-02 | 2014-08-26 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives |
| GB0905664D0 (en) * | 2009-04-02 | 2009-05-13 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2501696B1 (en) | 2009-10-15 | 2016-12-28 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| JP2011168515A (ja) | 2010-02-17 | 2011-09-01 | Kowa Co | エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物 |
| WO2012007510A1 (en) * | 2010-07-14 | 2012-01-19 | Bayer Pharma Aktiengesellschaft | Compounds for binding and imaging amyloid plaques and their use |
| KR20140001965A (ko) * | 2010-11-30 | 2014-01-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 바이시클릭 화합물 |
| CN102391260B (zh) | 2011-09-29 | 2014-12-10 | 上海交通大学 | 3-甲酮-6-取代-苯并呋喃类化合物及其制备方法和用途 |
| WO2013163244A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| US9370588B2 (en) | 2013-01-04 | 2016-06-21 | University Of Massachusetts | Luciferin amides |
| GB201306248D0 (en) * | 2013-04-05 | 2013-05-22 | Ucl Business Plc | Compounds and their uses |
| HK1222658A1 (zh) | 2013-07-17 | 2017-07-07 | Otsuka Pharmaceutical Co., Ltd. | 氰基三唑化合物 |
| AU2015308709B2 (en) | 2014-08-29 | 2020-01-02 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
| HUE056957T2 (hu) * | 2014-08-29 | 2022-04-28 | Chdi Foundation Inc | Próbák huntingtin fehérjét megjelenítõ képalkotásra |
| DK3197277T3 (da) | 2014-08-29 | 2022-01-31 | Chdi Foundation Inc | Prober til billeddannelse af huntingtin-protein |
| EP3186241B1 (en) | 2014-08-29 | 2020-10-07 | CHDI Foundation, Inc. | Probes for imaging huntington protein |
| PT3340796T (pt) | 2015-08-28 | 2021-07-28 | Chdi Foundation Inc | Sondas para imagens da proteína huntingtina |
-
2015
- 2015-08-28 HU HUE15836321A patent/HUE056957T2/hu unknown
- 2015-08-28 AU AU2015308774A patent/AU2015308774B2/en active Active
- 2015-08-28 KR KR1020177008383A patent/KR102456946B1/ko active Active
- 2015-08-28 CA CA2959501A patent/CA2959501C/en active Active
- 2015-08-28 HR HRP20211778TT patent/HRP20211778T1/hr unknown
- 2015-08-28 CN CN202310475134.8A patent/CN116655618B/zh active Active
- 2015-08-28 PT PT158363218T patent/PT3186233T/pt unknown
- 2015-08-28 CN CN201580058282.3A patent/CN107108534B/zh active Active
- 2015-08-28 EP EP15836321.8A patent/EP3186233B8/en active Active
- 2015-08-28 BR BR112017004141A patent/BR112017004141B8/pt active IP Right Grant
- 2015-08-28 EP EP21192872.6A patent/EP4006016A3/en not_active Withdrawn
- 2015-08-28 DK DK15836321.8T patent/DK3186233T3/da active
- 2015-08-28 KR KR1020227035965A patent/KR102586736B1/ko active Active
- 2015-08-28 US US15/507,208 patent/US10479802B2/en active Active
- 2015-08-28 SG SG11201701600QA patent/SG11201701600QA/en unknown
- 2015-08-28 WO PCT/US2015/047407 patent/WO2016033445A1/en not_active Ceased
- 2015-08-28 MX MX2017002703A patent/MX380810B/es unknown
- 2015-08-28 SI SI201531751T patent/SI3186233T1/sl unknown
- 2015-08-28 JP JP2017530971A patent/JP6817207B2/ja active Active
- 2015-08-28 EA EA201790407A patent/EA035646B1/ru unknown
- 2015-08-28 PL PL15836321T patent/PL3186233T3/pl unknown
- 2015-08-28 ES ES15836321T patent/ES2898965T3/es active Active
-
2017
- 2017-02-27 IL IL250803A patent/IL250803B/en active IP Right Grant
- 2017-02-28 MX MX2021003311A patent/MX2021003311A/es unknown
-
2019
- 2019-08-02 US US16/530,594 patent/US11059836B2/en active Active
-
2020
- 2020-12-24 JP JP2020214504A patent/JP7126541B2/ja active Active
-
2022
- 2022-08-05 US US17/881,895 patent/US12258355B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
| BR112017004136A2 (pt) | sondas para imageamento de proteína de huntingtina | |
| BR112017004134A2 (pt) | ?sondas para imageamento de proteína de huntingtina? | |
| IL282304A (en) | Topical pharmaceutical compositions | |
| IL270514B (en) | Agricultural compositions | |
| BR112017004140A2 (pt) | sondas para imageamento de proteína de huntingtina | |
| CY1123633T1 (el) | Ετεροκυκλικες ενωσεις και οι χρησεις αυτων | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| BR112018003331A2 (pt) | sondas para imagear proteína huntingtina | |
| UY37036A (es) | Compuestos inhibidores de la quinasa de unión a tank | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
| BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
| BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
| BR112017018872A2 (pt) | combinação de um antagonista pd-1 e eribulina para tratamento de câncer | |
| BR112016017620A2 (pt) | Composto esteroidal para uso no tratamento da encefalopatia hepática | |
| AR112602A1 (es) | ANTICUERPOS ANTI-TrkB | |
| BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
| BR112017002675A2 (pt) | métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila | |
| BR112018005299A2 (pt) | 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso | |
| BR112017001375A2 (pt) | agente farmacêutico | |
| IL252221B (en) | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| BR112017008811A2 (pt) | métodos para o tratamento de distúrbios renais | |
| BR112017004947A2 (pt) | composto ou sal farmaceuticamente aceitável, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento de mieloma múltiplo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2493 DE 16/10/2018 POR TER SIDO INDEVIDA. |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B15V | Prolongation of time limit allowed |
Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2487 DE 04/09/2018, COMUNICADO PUBLICADO NA RPI 2488 DE 11/09/2018 E RESOLUCAO INPI/PR NO 225/2018 FICAM DEVOLVIDOS ATE 14/09/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADOS DENTRO DOS COMUNICADOS. |
|
| B11N | Dismissal: publication cancelled [chapter 11.14 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2495 DE 30/10/2018 POR TER SIDO INDEVIDA. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2676 DE 19/04/2022 QUANTO AO INVENTOR POR ERRO MATERIAL DO REQUERENTE. |